Home | Volume 52 | Article number 74

Letter to the editors

Pilot screening for anti-HCV in adults at the Centre Médico-Chirurgical St-Damien in Ambanja, Madagascar

Pilot screening for anti-HCV in adults at the Centre Médico-Chirurgical St-Damien in Ambanja, Madagascar

Francesco De Maria1,&, Jeromine Jinoro2, Marie Vèronique Vavisoa2, Maria Benedicth Ampilaza2, Massimo Ciccozzi3, Giovanni Mottini4

 

1Department of Systems Medicine, “Tor Vergata” University, Rome, Italy, 2Centre Médico-Chirurgical St-Damien, Ambanja, Madagascar, 3Medical Statistics and Molecular Epidemiology Unit, University of Biomedical Campus, Rome, Italy, 4University Cooperation Office, University of Biomedical Campus, Rome, Italy

 

 

&Corresponding author
Francesco De Maria, Department of Systems Medicine, “Tor Vergata” University, Rome, Italy

 

 

To the editors of the Pan African Medical Journal    Down

Hepatitis C virus (HCV) infection remains a significant global public health problem, particularly in resource-limited countries. The World Health Organization (WHO) has set the goal of eliminating viral hepatitis as a health threat by 2030 [1]. The most recent guidelines recommend the use of rapid tests and simplified diagnostic algorithms, adaptable to low-resource settings [2]. In sub-Saharan Africa, where a substantial proportion of the world´s HCV-infected population is estimated to live, epidemiological data remain fragmented and often outdated [3,4].

In Madagascar, knowledge on HCV remains scarce: the only published study dates back more than fifteen years and reported an anti-HCV prevalence of 1.7% in the urban population of Antananarivo [5]. We conducted a cross-sectional study at the Centre Médico-Chirurgical St-Damien (CMC) in Ambanja, with the aim of updating knowledge on HCV prevalence in Madagascar. Consecutive adults attending the facility were enrolled. All participants underwent a rapid test for anti-HCV. In subjects with positive results, liver ultrasound was performed on site to evaluate the presence of structural abnormalities. Virological confirmation with HCV RNA could not be performed due to economic and logistical limitations, which prevented access to advanced molecular techniques. This limitation represents a methodological weakness but reflects the operational reality typical of resource-limited countries [6]. A total of 72 adults were consecutively enrolled over the two-day survey. Two participants tested positive for anti-HCV, corresponding to a prevalence of 2.8% (95% CI: 0.8-9.6). In both cases, liver ultrasound did not reveal any structural abnormalities.

This study provides new evidence on HCV circulation in Ambanja, Madagascar, with a prevalence of 2.8%. Although the sample size is small and not representative, this figure is slightly higher than that reported in Antananarivo more than fifteen years ago (1.7%) [5]. This suggests that the infection is present and detectable outside the capital and highlights the urgency of having updated data for different regions of the country.

This study confirms this critical issue: although serology could be performed, the absence of HCV RNA testing due to economic constraints prevented diagnostic confirmation, reflecting a common scenario in resource-limited contexts [6]. As emphasized in the 2018 WHO guidelines, access to molecular testing and antiviral therapies should be a priority, even in low-income countries [7]. Liver ultrasounds of the two positive subjects were normal, suggesting the absence of advanced disease.

However, without virological confirmation, it is not possible to distinguish between past and active infection. These findings emphasize the urgency of conducting larger epidemiological studies, strengthening diagnostic capacity, and ensuring better access to care, in line with the WHO goal of eliminating viral hepatitis by 2030 [1,2,6,7]. However, conducting research in resource-limited countries such as Madagascar remains particularly challenging due to restricted access to diagnostics and treatments [8].

 

 

Competing interest    Down

The authors declare no competing interests.

 

 

Authors´ contributions Up    Down

Francesco De Maria conceived the study, performed data analysis and drafted the manuscript. Jeromine Jinoro, Marie Vèronique Vavisoa and Maria Benedicth Ampilaza contributed to data collection and manuscript editing. Massimo Ciccozzi provided scientific supervision, methodology support and critical review of the manuscript. Giovanni Mottini secured funding from the University and supervised project administration. All the authors read and approved the final version of this manuscript.

 

 

Acknowledgements Up    Down

We would like to express our sincere gratitude to the Campus Bio-Medico University of Rome and its students for their active contribution to this work: Olga Ciavarella, Matteo Ferri, Dafne Marcelli, Cristina Melloni, Francesco Mendicelli, Martina Pacillo, Eugenio Refrigeri, Chiara Repaci, Alessandro Ruggero, Maria francesca Russo, and Andrea Salvatori. We are also deeply grateful to the Centre Mdico-Chirurgical St-Damien of Ambanja for its invaluable support in the implementation of this study.

 

 

References Up    Down

  1. World Health Organization. Global health sector strategy on viral hepatitis 2016-2021: towards ending viral hepatitis. Geneva: World Health Organization; 2016. Accessed September 16, 2025.

  2. World Health Organization. Guidelines on hepatitis B and C testing. Geneva: World Health Organization; 2017. Accessed September 16, 2025.

  3. Petruzziello A, Marigliano S, Loquercio G, Cozzolino A, Cacciapuoti C. Global epidemiology of hepatitis C virus infection: an up-date of the distribution and circulation of hepatitis C virus genotypes. World J Gastroenterol. 2016 Sep 14;22(34):7824-40. PubMed | Google Scholar

  4. Polaris Observatory HCV Collaborators. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. PubMed | Google Scholar

  5. Ramarokoto CE, Rakotomanana F, Ratsitorahina M, Raharimanga V, Razafindratsimandresy R, Randremanana R et al. Seroprevalence of hepatitis C and associated risk factors in urban areas of Antananarivo, Madagascar. BMC Infect Dis. 2008 Feb 29;8:25. PubMed | Google Scholar

  6. World Health Organization. Global hepatitis report, 2017. Geneva: World Health Organization; 2017. Accessed September 16, 2025.

  7. World Health Organization. Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: World Health Organization; 2018 Jul 1. Accessed September 16, 2025.

  8. De Maria F, Rico González F, Namuwonge AJ, Serraino R, Torti C. Screening for anti-HCV antibodies in a cohort of people living with HIV at “Zia Angelina“ Medical Centre, Kampala, Uganda. Pan Afr Med J. 2025 Aug 5;51:85 PubMed | Google Scholar